↓ Skip to main content

Estimating the Effect of Intravenous Acetaminophen for Postoperative Pain Management on Length of Stay and Inpatient Hospital Costs

Overview of attention for article published in Advances in Therapy, November 2016
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (68th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (58th percentile)

Mentioned by

policy
1 policy source
twitter
2 X users

Citations

dimensions_citation
48 Dimensions

Readers on

mendeley
84 Mendeley
Title
Estimating the Effect of Intravenous Acetaminophen for Postoperative Pain Management on Length of Stay and Inpatient Hospital Costs
Published in
Advances in Therapy, November 2016
DOI 10.1007/s12325-016-0438-y
Pubmed ID
Authors

E. Eve Shaffer, An Pham, Robert L. Woldman, Andrew Spiegelman, Scott A. Strassels, George J. Wan, Thomas Zimmerman

Abstract

The provision of safe, effective, cost-efficient perioperative inpatient acute pain management is an important concern among clinicians and administrators within healthcare institutions. Overreliance on opioid monotherapy in this setting continues to present health risks for patients and increase healthcare costs resulting from preventable adverse events. The goal of this study was to model length of stay (LOS), potential opioid-related complications, and costs for patients reducing opioid use and adding intravenous acetaminophen (IV APAP) for management of postoperative pain. Data for this study were de-identified inpatient encounters from The Advisory Board Company across 297 hospitals from 2012-2014, containing 2,238,433 encounters (IV APAP used in 12.1%). Encounters for adults ≥18 years of age admitted for cardiovascular, colorectal, general, obstetrics and gynecology, orthopedics, or spine surgery were included. The effects of reducing opioids and adding IV APAP were estimated using hierarchical statistical models. Costs were estimated by multiplying modeled reductions in LOS or complication rates by observed average volumes for medium-sized facilities, and by average cost per day or per complication (LOS: US$2383/day; complications: derived from observed charges). Across all surgery types, LOS showed an average reduction of 18.5% (10.7-32.0%) for the modeled scenario of reducing opioids by one level (high to medium, medium to low, or low to none) and adding IV APAP, with an associated total LOS-related cost savings of $4.5 M. Modeled opioid-related complication rates showed similar improvements, averaging a reduction of 28.7% (5.4-44.0%) with associated cost savings of $0.2 M. In aggregate, costs decreased by an estimated $4.7 M for a medium-sized hospital. The study design demonstrates associations only and cannot establish causal relationships. The cost impact of LOS is modeled based on observed data. This investigation indicates that reducing opioid use and including IV APAP for postoperative pain management has the potential to decrease LOS, opioid-related complication rates, and costs from a hospital perspective. Mallinckrodt Pharmaceuticals.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 84 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 1%
Unknown 83 99%

Demographic breakdown

Readers by professional status Count As %
Student > Postgraduate 10 12%
Other 9 11%
Student > Ph. D. Student 8 10%
Researcher 8 10%
Student > Doctoral Student 8 10%
Other 19 23%
Unknown 22 26%
Readers by discipline Count As %
Medicine and Dentistry 27 32%
Pharmacology, Toxicology and Pharmaceutical Science 12 14%
Nursing and Health Professions 9 11%
Biochemistry, Genetics and Molecular Biology 3 4%
Engineering 2 2%
Other 7 8%
Unknown 24 29%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 August 2020.
All research outputs
#7,310,239
of 25,998,826 outputs
Outputs from Advances in Therapy
#669
of 2,677 outputs
Outputs of similar age
#101,686
of 323,658 outputs
Outputs of similar age from Advances in Therapy
#19
of 46 outputs
Altmetric has tracked 25,998,826 research outputs across all sources so far. This one has received more attention than most of these and is in the 71st percentile.
So far Altmetric has tracked 2,677 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.1. This one has gotten more attention than average, scoring higher than 74% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 323,658 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.
We're also able to compare this research output to 46 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 58% of its contemporaries.